The Centre for Protein Degradation
The Centre for Protein Degradation is a centre of excellence coordinating all aspects of molecularly driven protein degradation, from concept to clinic, both within and beyond the ICR.
Targeted protein degradation has emerged as a powerful and transforming approach to deliver new medicines for cancer patients, and our scientists have been amongst the pioneers in this field. MRT-2359, a drug currently undergoing Phase I clinical trial was discovered following a research programme at the ICR. In 2022, the Centre for Protein Degradation was established with generous philanthropic funding from Ruth and David Hill.
The Centre for Protein Degradation aims are to:
- discover new therapeutic approaches that explore targeted protein degradation for cancer patients
- develop new protein degradation approaches.
The Centre for Protein Degradation has 17 dedicated posts (currently 11 filled) and is co-located and closely linked with the Centre of Cancer Drug Discovery. The Centre for Protein Degradation is designed to be very collaborative. Its members work with several leading cancer research teams in and outside the ICR and with clinical scientists at our hospital partner, The Royal Marsden, to achieve the Centre’s aims.
Contact us LinkedIn